Sightera Biosciences Lands €3 Mn Pre-Seed to Expand AI Drug Discovery Platform

The funding round was led by Entourage, Anacura, and QBIC.

The new funding will help Sightera expand its team, improve its AI-powered drug discovery platform, develop new preclinical drug candidates, and strengthen partnerships with pharmaceutical and biotech companies.

Pieterjan Bouten, General Partner at Entourage, said, “At Entourage, we back founders who rethink entire industries from first principles. Sightera doesn’t ask AI to predict biology. It lets biology teach AI. That’s a fundamentally different approach to drug discovery. By learning directly from real patient biology, Sightera can identify promising new molecules in months instead of years. That speed matters. As billions in blockbuster drug revenues approach the patent cliff pharma urgently needs a faster path to the next generation of medicines. We believe Sightera is built for exactly that moment.”

“Many AI drug discovery platforms begin by designing novel molecules against a predefined biological target and only then evaluate their activity in complex biological models. At Sightera, we reverse that paradigm. We start with complex patient-derived biology, learn directly from therapeutic responses in patient-derived biology, and use those insights to design entirely new small molecules. Our goal is not simply to accelerate drug discovery, but to improve the probability of clinical success by placing human disease biology at the very beginning of the drug discovery process,” said Vercammen.

Founded in 2025 by Hendrik Vercammen (CEO), Maxim Le Compte (CSO), Lars Vanlommel (CBO), and Christophe Deben (CDO), Sightera Biosciences is an AI-powered drug discovery company that uses patient data and artificial intelligence to develop new medicines.

The company builds its own drug research datasets to train its AI models, helping create first-in-class small molecule drugs designed for specific patient groups based on their biomarkers.